It refers to the derivatives of difluorocyclopentadiol and difluorobenzo-p-dioxin (I), wherein R1, R2, R3, R4, R5 and N are described below. 5-o-o-o-o-o-o-o-phenylbenzene benzene benzene benzene benzene benzene benzene 5,5,5-4-4-4-4-4-4-47,7a hexahydro cycloopenta [e] [1, （3）Oxazin-4-il）-4-fluoro-fenil]-5-fluoroometil-pirazina-2-carboxilico；There are others He also mentioned pharmacology composers These compounds have inhibitory effects on the treatment of Alzheimer's disease 1SE REFIERE A DERIVADOS DE DIFLUORO-CICLOPENTAOXACINILOS Y DIFLUOROENZOOXACINILOS DE FORMULA (I) DONDE R1, R2, R3, R4, R5 Y n SON COMO SE DESCRIBEN EN EL PRESENTE. SON COMPUESTOS PREFERIDOS: [3-((4S,4aR,7aR)-2-AMINO-5,5-DIFLUORO-4-METIL-4,4a,5,6,7,7a-HEXAHIDRO-CICLOPENTA[e][1,3]OXAZIN-4-IL)-4-FLUORO-FENIL]-AMIDA DEL ACIDO 5-BUT-2-INILOXI-PIRAZINA-2-CARBOXILICO； [3-((4S,4aR,7aR)-2-AMINO-5,5-DIFLUORO-4-METIL-4,4a,5,6,7,7a-HEXAHIDRO-CICLOPENTA[e][1,3]OXAZIN-4-IL)-4-FLUORO-FENIL]-AMIDA DEL ACIDO 5-FLUOROMETIL-PIRAZINA-2-CARBOXILICO； ENTRE OTROS. TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA BACE1 SIENDO UTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
